Johnson & Johnson
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
March 4, 2024Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …
FDA approves Balversa for bladder cancer treatment
January 22, 2024Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer
Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
J&J vaccine halted in US due to blood clots
April 14, 2021Research and Development CDC, COVID-19 vaccine, FDA, Janssen, Johnson & Johnson, pharma, pharma news
The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …
J & J to ship up to 400 million vaccines to Africa
March 30, 2021Manufacturing and Production COVAX, COVID-19, COVID-19 vaccine, Janssen, Johnson & Johnson
Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …
Janssen’s multiple sclerosis treatment recommended by EMA
March 29, 2021Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis
Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …
AstraZeneca and J&J COVID-19 vaccines face viral vector shortage
March 25, 2021Astrazenaca, COVID-19, Johnson & Johnson, Vaccine
Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity …
Johnson & Johnson’s arthritis drug shows promising results in Phase III trial
March 16, 2021Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.
J&J’s one-shot COVID-19 vaccine approved by European Commission
March 12, 2021Medical Communications COVID-19, EMA, Johnson & Johnson
The European Commission has granted Johnson and Johnson’s single-shot COVID-19 vaccine Conditional Marketing Authorisation (CMA), it was announced on Thursday. …
FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use
March 1, 2021Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines
The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …
J&J’s one-shot COVID-19 vaccine submitted to the EU
February 17, 2021Research and Development COVID, COVID Vaccine, COVID-19, Johnson & Johnson, Vaccine
Johnson & Johnson has applied to the EMA for marketing authorisation of their one-shot COVID-19 vaccine in Europe.
Johnson & Johnson’s single-shot COVID-19 vaccine 85% effective
February 1, 2021Sales and Marketing COVID-19, Johnson & Johnson, vaccines
Johnson & Johnson has announced that its COVID-19 vaccine candidate is 85% effective in preventing serious symptoms of the disease, …
Johnson & Johnson selects lead COVID-19 vaccine candidate and targets September Phase I study
March 31, 2020Manufacturing and Production . Johnson & Johnson, Johnson & Johnson, Vaccine, coronavirus, coronavirus vaccine
Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been …
New Johnson & Johnson study aiming to add stroke detection to Apple Watch
February 26, 2020Research and Development Apple, Janssen, Johnson & Johnson, apple watch, iphone, stroke
Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection. It …
Jury orders Johnson & Johnson to pay $750 million in latest baby powder case
February 7, 2020Medical Communications J&J, JJ, Johnson & Johnson, ovarian cancer, talc, talc powder
Johnson & Johnson have been ordered to pay by a jury $750 million to four plaintiffs over the company’s baby …
Johnson & Johnson CEO testifies for the first time in Baby Powder Cancer trial
January 28, 2020Manufacturing and Production J&J, JJ, Johnson & Johnson, Talc Powder Cancer, baby powder, talc powder
Johnson & Johnson CEO Alex Gorsky faced questions around stock sales and his knowledge of asbestos in the company’s baby …
